Opinion Research

 
News Articles for Opinion Research top ^
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, announced today that it will host a Key Opinion Leader Breakfast on Tuesday, October 14, 2014 from 8:00-9:30 a.m. Eastern time in New York City.
Sign-up for Ignyta to Host Investor Meeting with Oncology Key Opinion Leaders on October 14, 2014 investment picks
Celgene International Sàrl (NASDAQ: CELG), a wholly-owned subsidiary of Celgene Corporation, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for OTEZLA® (apremilast), the Company’s oral selective inhibitor of phosphodiesterase 4 (PDE4), in two therapeutic indications: 1 Psoriasis is an immune mediated skin condition characterised by raised scaly lesions on the skin.
Sign-up for Celgene Receives Positive CHMP Opinion for OTEZLA® (apremilast), the First Oral PDE4 Inhibitor for the Treatment of Patients with Psoriasis and Psoriatic Arthritis investment picks
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency, has adopted a positive opinion on the company’s Marketing Authorization Application (MAA) for Harvoni ® , an investigational once-daily tablet combining the NS5A inhibitor ledipasvir (LDV) 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir (SOF) 400 mg, for the treatment of chronic hepatitis C virus (HCV) infection in adults.
Sign-up for European CHMP Adopts Positive Opinion for Gilead’s Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection in Adults investment picks
2014/10/15
The French journalist who was reported to have made a link between Michael Schumacher's brain injury in a skiing accident and the GoPro camera he was wearing on his helmet has taken to Twitter to clarify that he was stating his own opinion, and not quoting Schumacher's son, as previously reported.
Sign-up for UPDATE: Reporter says linking Schumacher injury to GoPro was his opinion investment picks
2014/10/15
The French journalist who was reported to have made a link between Michael Schumacher's brain injury in a skiing accident and the GoPro camera he was wearing on his helmet has taken to Twitter to clarify that he was stating his own opinion, and not quoting Schumacher's son, as previously reported.
Sign-up for Reporter says linking Schumacher injury to GoPro was his opinion investment picks
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted its final opinion on Iclusig ® (ponatinib) following the recommendations made by the Pharmacovigilance Risk Assessment Committee (PRAC) earlier this month.
Sign-up for ARIAD Announces Adoption of Final Opinion for Iclusig by Committee for Medicinal Products for Human Use in Europe investment picks
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs primarily in the infectious disease field, today announced that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted positive opinions for AbbVie’s investigational, all-oral, interferon-free treatment of VIEKIRAX™ (a combination of ombitasvir, paritaprevir (ABT-450) and ritonavir) plus EXVIERA™ (dasabuvir), with or without ribavirin (RBV), for patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, and VIEKIRAX™ only, with RBV, for patients with genotype 4 (GT4) HCV infection.
Sign-up for Enanta Announces CHMP Grants Positive Opinions of AbbVie’s VIEKIRAX™ (ombitasvir/paritaprevir(ABT-450)/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe investment picks
Genzyme , a Sanofi company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of Cerdelga ® (eliglustat) capsules, an oral treatment for certain adults living with Gaucher disease type 1.
Sign-up for European CHMP Adopts Positive Opinion for Genzyme’s Cerdelga® (eliglustat) Capsules investment picks
EpiFix® shown to result in the most rapid improvement and resolution of DFUs, successful complex management of extensive life-threatening wounds, and safe and effective treatment of Stage IV Pressure Ulcers MARIETTA, Ga.
Sign-up for MiMedx At Fall 2014 SAWC: Studies And Key Opinion Leaders Present Clinical Evidence Of EpiFix Healing Results On Chronic And Acute Wounds investment picks
VICTORIA, British Columbia, Oct.
Sign-up for Aurinia Pharmaceuticals to Host Lupus Opinion Leader Meeting and Webcast on October 23 in New York City investment picks
REHOVOT, Israel, and BRIDGEWATER, N.J., Oct.
Sign-up for Foamix Pharmaceuticals to Host Key Opinion Leader Meeting and Webcast on November 4th in New York City investment picks
- Major regulatory milestone achieved toward approval in the European Union - Final decision from the European Commission expected in the first quarter of 2015 NORTH CHICAGO, Ill.
Sign-up for CHMP Grants Positive Opinions of AbbVie's VIEKIRAX™ (ombitasvir/paritaprevir/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe investment picks
NEW YORK, Nov.
Sign-up for NeoStem to Host Key Opinion Leader Event Webcast on December 1, 2014 investment picks
-- Mark Pimentel, M.D., FRCP(C), of Cedars-Sinai Medical Center Serves as Chairman --
Sign-up for Synthetic Biologics Appoints Prominent Gastrointestinal (GI) Key Opinion Leaders to Irritable Bowel Syndrome (IBS) Clinical Advisory Board investment picks
FARMINGDALE, N.Y. , Oct.
Sign-up for Misonix Key Opinion Leaders Train New Users at the Congress of Neurological Surgeons Annual Meeting investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Opinion Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Operations Research  |  Next: Opportunities Companies